A proposed model for endometrial serous carcinogenesis

American Journal of Surgical Pathology

Volumn 35, Issue 1, 2011, Pages

  Zheng, Wenxin ^a,b,c,d   Xiang, Li ^a,d   Fadare, Oluwole ^e   Kong, Beihua ^d  

^a Department of Pharmacology and the Comprehensive Cancer Center   (United States)

^b Department of Obstetrics and Gynecology ^*  (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SHANDONG UNIVERSITY   (China)

Author keywords

endometrial cancer; endometrial glandular dysplasia; endometrial intraepithelial carcinoma; endometrial papillary serous carcinoma; endometrial serous carcinogenesis

Indexed keywords

TUMOR MARKER;

ARTICLE; BIOLOGICAL MODEL; CELL TRANSFORMATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PRECANCER; SIGNAL TRANSDUCTION;

CARCINOMA, ENDOMETRIOID; CELL TRANSFORMATION, NEOPLASTIC; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; PRECANCEROUS CONDITIONS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 78650878985     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318202772e     Document Type: Article

References (120)

1. Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol. 2004;23:110-118.
2. Ambros RA, Sherman ME, Zahn CM, et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995;26:1260-1267.
3. Arai M, Utsunomiya J, Miki Y. Familial breast and ovarian cancers. Int J Clin Oncol. 2004;9:270-282.
4. Baergen RN, Warren CD, Isacson C, et al. Early uterine serous carcinoma: clonal origin of extrauterine disease. Int J Gynecol Pathol. 2001;20:214-219.
5. Berman JJ, Albores-Saavedra J, Bostwick D, et al. Precancer: a conceptual working definition - results of a Consensus Conference. Cancer Detect Prev. 2006;30:387-394.
6. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10-17.
7. Carcangiu ML, Tan LK, Chambers JT. Stage IA uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol. 1997;21: 1507-1514.
8. Casalini P, Iorio MV, Galmozzi E, et al. Role of HER receptors family in development and differentiation. J Cell Physiol. 2004;200:343-350.
9. Chan JK, Loizzi V, Youssef M, et al. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol. 2003;90:181-185.
10. Chan JK, Manuel MR, Cheung MK, et al. Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes? Gynecol Oncol. 2006;102:508-512.
11. Chen EY, Mehra K, Mehrad M, et al. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol. 2010;222:110-116.
12. Chiesa-Vottero AG, Malpica A, Deavers MT, et al. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol. 2007;26:328-333. (Pubitemid 46986071)
13. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. Int J Gynaecol Obstet. 2003;83(suppl 1):79-118.
14. Crum CP, Lee KR, eds. Diagnostic Gynecologic and Obstetric Pathology. Philadelphia, PA: Elsevier; 2009:545-610.
15. Curtis R, Ron E, Hankey B, et al. New malignancies following breast cancer. NCI, SEER Registries. 1973-2000;7:181-205.
16. Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol. 2004;28:1568-1578.
17. Demopoulos RI, Mesia AF, Mittal K, et al. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis. Int J Gynecol Pathol. 1999;18: 233-237.
18. Dupont J, Wang X, Marshall DS, et al. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol Oncol. 2004;94: 449-455.
19. Eifel PJ, Ross J, Hendrickson M, et al. Adenocarcinoma of the endometrium: analysis of 256 cases with disease limited to the uterine corpus: treatment comparisons. Cancer. 1983;52:1026-1031.
20. Esteller M, Levine R, Baylin SB, et al. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene. 1998;17: 2413-2417.
21. Ettinger B, Golditch IM, Friedman G. Gynecologic consequences of long-term, unopposed estrogen replacement therapy. Maturitas. 1988;10:271-282.
22. Fadare O, Zheng W. Endometrial glandular dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of Type II endometrial cancers. Diagn Pathol. 2008;3:6.
23. Fadare O, Zheng W. Insights into endometrial serous carcinogenesis and progression. Int J Clin Exp Pathol. 2009;2:411-432.
24. Faquin WC, Fitzgerald JT, Boynton KA, et al. Intratumoral genetic heterogeneity and progression of endometrioid type endometrial adenocarcinomas. Gynecol Oncol. 2000;78:152-157.
25. Fukuchi T, Sakamoto M, Tsuda H, et al. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res. 1998;58: 3526-3528.
26. Gambrell RD Jr. Estrogens, progestogens and endometrial cancer. J Reprod Med. 1977;18:301-306.
27. Garg K, Leitao MM Jr, Wynveen CA, et al. p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol. 2010;23:80-92.
28. Gehrig PA, Groben PA, Fowler WC Jr, et al. Noninvasive papillary serous carcinoma of the endometrium. Obstet Gynecol. 2001;97:153-157.
29. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol. 1994;54: 264-268.
30. Goshen R, Chu W, Elit L, et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol. 2000;79:477-481.
31. Guida M, Sanguedolce F, Bufo P, et al. Aberrant DNA hypermethylation of hMLH-1 and CDKN2A/p16 genes in benign, premalignant and malignant endometrial lesions. Eur J Gynaecol Oncol. 2009;30:267-270.
32. Hall HI, Jamison P, Weir HK. Second primary ovarian cancer among women diagnosed previously with cancer. Cancer Epidemiol Biomark Prev. 2001;10:995-999.
33. Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science. 1993;262:1980-1981.
34. Hashi A, Yuminamochi T, Murata S, et al. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol. 2003;22:374-377.
35. Hendrickson M,Ross J, Eifel P, et al., Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma, Am J Surg Pathol, 1982, 6, 93-108.
36. Holcomb K, Delatorre R, Pedemonte B, et al. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet Gynecol. 2002;100:1290-1295.
37. Hornreich G, Beller U, Lavie O, et al. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol Oncol. 1999;75:300-304.
38. Hui P, Kelly M, O'Malley DM, et al. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol. 2005;18:75-82.
39. Huszar M, Pfeifer M, Schirmer U, et al. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol. 2010;220:551-561.
40. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol. 2008;27:1-9.
41. Jarboe EA, Miron A, Carlson JW, et al. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathol. 2009; 28:308-315.
42. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
43. Jia L, Liu Y, Yi X, et al. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res. 2008;14:2263-2269.
44. Jiang T, Chen N, Zhao F, et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 2010;70:5486-5496.
45. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNAbinding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006;7: 556-564.
46. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol. 2001; 25:884-891.
47. Keating JT, Ince T, Crum CP. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol. 2001;8:83-92.
48. Kim SS, Cao L, Li C, et al. Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1. Mol Cell Biol. 2004;24:9498-9507.
49. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-169.
50. Konecny GE, Agarwal R, Keeney GA, et al. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. Gynecol Oncol. 2008;109:263-269.
51. Konopka B, Janiec-Jankowska A, Czapczak D, et al. Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations. J Cancer Res Clin Oncol. 2007;133:361-371.
52. Kupryjanczyk J, Thor AD, Beauchamp R, et al. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. Mod Pathol. 1996;9:166-173.
53. Lavie O, Hornreich G, Ben-Arie A, et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol. 2004;92:521-524.
54. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004;444:213-223.
55. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol. 1997;81:228-232.
56. Lax SF, Pizer ES, Ronnett BM, et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol. 1998; 29:551-558.
57. Lee KR, Belinson JL. Recurrence in noninvasive endometrial carcinoma: relationship to uterine papillary serous carcinoma. Am J Surg Pathol. 1991;15:965-973.
58. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26-35.
59. Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002;87:52-56.
60. Levine DA, Lin O, Barakat RR, et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol. 2001;80: 395-398.
61. Liang S, Pearl M, Liang S, et al. Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women
62. Liang SX, Chambers SK, Cheng L, et al. Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features. Int J Surg Pathol. 2004; 12:319-331.
63. Liang SX, Cheng L, Chambers SK, et al. Endometrial glandular dysplasia, a newly defined precursor lesion of uterine papillary serous carcinoma: Part II, molecular features. Intl J Surg Pathol. 2004;12:319-331.
64. Liu FS. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol. 2007;46:26-32.
65. Liu FS, Ho ES, Shih RT, et al. Mutational analysis of the BRCA1 tumor suppressor gene in endometrial carcinoma. Gynecol Oncol. 1997;66:449-453.
66. Massuger L, Roelofsen T, Ham M, et al. The origin of serous ovarian cancer may be found in the uterus: a novel hypothesis. Med Hypotheses. 2010;74:859-861.
67. Maxwell GL, Chandramouli GV, Dainty L, et al. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Clin Cancer Res. 2005;11: 4056-4066.
68. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236.
69. Mehrad M, Ning G, Chen EY, et al. A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. Adv Anat Pathol. 2010;17: 293-302.
70. Mell LK, Meyer JJ, Tretiakova M, et al. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res. 2004;10:5546-5553.
71. Menard S, Casalini P, Campiglio M, et al. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci. 2004;61: 2965-2978.
72. Mueller-Pillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 1999;88:95-99.
73. Mutter GL. Pten, a protean tumor suppressor. Am J Pathol. 2001; 158:1895-1898.
74. Negri G, Egarter-Vigl E, Kasal A, et al. p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations. Am J Surg Pathol. 2003;27:187-193.
75. Nielsen J, Christiansen J, Lykke-Andersen J, et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999;19:1262-1270.
76. Nofech-Mozes S, Khalifa MA, Ismiil N, et al. Immunophenotyping of serous carcinoma of the female genital tract. Mod Pathol. 2008;21:1147-1155.
77. Nordstrom B, Strang P, Lindgren A, et al. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression. Anticancer Res. 1996;16:899-904.
78. Odicino FE, Bignotti E, Rossi E, et al. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcriptionpolymerase chain reaction, and fluorescence in situ hybridization. Int J Gynecol Cancer. 2008;18:14-21.
79. Pietsch EC, Sykes SM, McMahon SB, et al. The p53 family and programmed cell death. Oncogene. 2008;27:6507-6521.
80. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst. 1996;88:1127-1135.
81. Quddus MR, Sung CJ, Zhang C, et al. Minor serous and clear cell components adversely affect prognosis in "mixed-type" endometrial carcinomas: a clinicopathologic study of 36 stage-I cases. Reprod Sci. 2010;17:673-678.
82. Rangel LB, Agarwal R, D'Souza T, et al. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res. 2003;9:2567-2575.
83. Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006;19:1091-1100.
84. Risinger JI, Hayes AK, Berchuck A, et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997;57:4736-4738.
85. Rolitsky CD, Theil KS, McGaughy VR, et al. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol. 1999;18:138-143.
86. Sakuragi N, Nishiya M, Ikeda K, et al. Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecol Oncol. 1994;53:183-189.
87. Santin AD, Bellone S, Gokden M, et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002;8: 1271-1279.
88. Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 2004;112: 14-25.
89. Santin AD, Bellone S, Siegel ER, et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/ neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol. 2005;192:813-818.
90. Santin AD, Zhan F, Cane S, et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer. 2005;92:1561-1573.
91. Santin AD, Bellone S, Marizzoni M, et al. Overexpression of claudin- 3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using clostridium perfringens enterotoxin (CPE). Cancer. 2007;109:1312-1322.
92. Sasano H, Comerford J, Wilkinson DS, et al. Serous papillary adenocarcinoma of the endometrium: analysis of proto-oncogene amplification, flow cytometry, estrogen and progesterone receptors, and immunohistochemistry. Cancer. 1990;65:1545-1551.
93. Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer. 2006;6:360-368.
94. Sherman ME, Bitterman P, Rosenshein NB, et al. Uterine serous carcinoma: a morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol. 1992;16:600-610.
95. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol. 1995;26:1268-1274.
96. Shifren JL, Schiff I. Role of hormone therapy in the management of menopause. Obstet Gynecol. 2010;115:839-855.
97. Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol. 1990;3:120-128.
98. Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91:463-469.
99. Soslow RA, Shen PU, Isacson C, et al. The CD44v6-negative phenotype in high-grade uterine carcinomas correlates with serous histologic subtype. Mod Pathol. 1998;11:194-199.
100. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997;57:3935-3940.
101. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol. 1997;150:177-185.
102. Tavassoli FA, Devilee P; World Health organization Classification of tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003.
103. Ueda SM, Kapp DS, Cheung MK, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008;198:218e211- 218e216.
104. Velasco A, Bussaglia E, Pallares J, et al. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol. 2006;37:1465-1472.
105. Vikesaa J, Hansen TV, Jonson L, et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. Embo J. 2006; 25:1456-1468.
106. Villella JA, Cohen S, Smith DH, et al. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer. 2006;16:1897-1902.
107. Von Wachenfeldt A, Lindblom A, Gronberg H, et al. A hypothesis-generating search for new genetic breast cancer syndromes: a national study in 803 Swedish families. Hered Cancer Clin Pract. 2007;5:17-24.
108. Wang XJ, Sun Z, Villeneuve NF, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis. 2008;29:1235-1243.
109. Wheeler DT, Bell KA, Kurman RJ, et al. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol. 2000;24:797-806.
110. Yaniv K, Yisraeli JK. The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene. 2002;287:49-54.
111. Yaniv K, Fainsod A, Kalcheim C, et al. The RNA-binding protein Vg1 RBP is required for cell migration during early neural development. Development. 2003;130:5649-5661.
112. Yemelyanova A, Ji H, Shih Ie M, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol. 2009;33:1504-1514.
113. Yi X, Zheng W. Endometrial glandular dysplasia and endometrial intraepithelial neoplasia. Curr Opin Obstet Gynecol. 2008; 20:20-25.
114. Zhang X, Liang SX, Jia L, et al. Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium. Am J Pathol. 2009;174:2000-2006.
115. Zheng W, Cao P, Zheng M, et al. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol. 1996;61:167-174.
116. Zheng W, Khurana R, Farahmand S, et al. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol. 1998;22:1463-1473.
117. Zheng W, Liang SX, Yu H, et al. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol. 2004; 12:207-223. (Pubitemid 39063348)
118. Zheng W, Schwartz PE. Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. Gynecol Oncol. 2005;96:579-582.
119. Zheng W, Liang SX, Yi X, et al. Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma. Int J Gynecol Pathol. 2007;26:38-52.
120. Zheng W, Yi X, Fadare O, et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 2008;32:304-315.